What is neuroblastoma?
Neuroblastoma is a cancer that develops from immature nerve cells called neuroblasts. These cells belong to the sympathetic nervous system, the part of the nervous system that controls automatic functions such as heart rate and blood pressure.
The tumour most often starts in one of the adrenal glands, which sit on top of the kidneys. It can also grow from the chains of nerve tissue that run alongside the spine in the neck, chest, abdomen or pelvis.
Neuroblastoma is the most common solid cancer outside the brain in infants and young children. It accounts for roughly 6-10% of all childhood cancers and is the most frequently diagnosed cancer in babies under one year old.
Its behaviour varies more than almost any other cancer. Some tumours in infants shrink or mature on their own without treatment, while others in older children grow quickly and resist therapy.
Epidemiology and Etiology
Neuroblastoma primarily affects very young children. The median age at diagnosis is approximately 17-18 months, with about 90% of cases diagnosed before age 5. Incidence is highest in the first year of life, and overall about 1 in 7,000 children develops neuroblastoma.
Slightly more males are affected than females (ratio ~1.2:1). While the exact cause remains largely unknown, neuroblastoma is considered a disorder of embryonic development where neuroblasts fail to differentiate and mature properly, leading to uncontrolled proliferation.
| Factor | Details |
|---|---|
| Genetics | Mostly sporadic; 1–2% familial, usually ALK or PHOX2B germline mutations; familial cases present earlier and may be multifocal. Common variants (e.g. LMO1) slightly raise risk. |
| Associated conditions | Hirschsprung disease, congenital central hypoventilation (PHOX2B), possibly NF1, Beckwith-Wiedemann and other overgrowth syndromes. |
| Environment | No proven environmental cause; most cases arise from random mutations during fetal development. |
Understanding that neuroblastoma originates from the developing nervous system is key to grasping its variable presentation and behavior. The tumor’s biological aggressiveness is heavily influenced by the genetic and molecular characteristics of these immature neuroblasts at the time of transformation.
How Does It Look? (Gross and Microscopic Appearance)
In a child, the tumour itself is usually hidden deep inside the body. What parents may notice is a swollen or hard belly, a lump in the neck, bluish bumps under the skin of a baby, or bruising and puffiness around the eyes.
Doctors and pathologists describe the tumour in two ways: how it looks to the naked eye during surgery or on scans, and how it looks under the microscope.
| Feature | Naked-eye appearance |
|---|---|
| Location | Adrenal gland (35–40%); spinal sympathetic chain in abdomen (25–30%), chest (15–20%), neck (5–10%), pelvis (rare). |
| Size and shape | From under 3 cm to masses filling the abdomen; often lobulated. |
| Cut surface | Firm, grey-white or tan, with bleeding, necrosis and sometimes cysts. |
| Calcification | In 50–80% on imaging; a key diagnostic clue. |
| Relationship to tissues | Encases vessels (aorta, vena cava) and invades locally rather than forming a capsule. |
| Microscopic feature | Details |
|---|---|
| Cells | “Small round blue cells”: immature neuroblasts with dark nuclei and scant cytoplasm. |
| Homer-Wright rosettes | Cells around a core of fibrillary neuropil; strongly suggest neuroblastoma. |
| Neuropil | Fibrillary matrix showing neural differentiation. |
| INPC (Shimada) classification | Based on stroma, differentiation, MKI (over 200 per 5,000 cells is unfavourable) and age. |
| Stains | Positive: PHOX2B, synaptophysin, chromogranin A, NSE. Negative: CD45 and other lymphoid markers. |
The combination of small round neuroblastic cells, Homer-Wright rosettes, neuropil and the typical immunohistochemical markers confirms the diagnosis.
The degree of differentiation also matters. Tumours rich in mature ganglion cells and Schwann cell stroma usually behave better, and together with the MKI this still feeds into risk assignment alongside the molecular tests.
Symptoms
Symptoms of neuroblastoma vary widely. They depend mainly on the primary tumor location, the presence of metastasis, and any paraneoplastic syndromes (symptoms caused by substances the tumour releases).
Early symptoms are often vague and look like common childhood illnesses, which can delay diagnosis. There is no single “classic” symptom.
| Tumour site | Typical symptoms |
|---|---|
| Abdomen (most common) | Swollen tummy or firm lump, pain, early fullness, constipation, urinary problems; sometimes high blood pressure. |
| Chest | Cough, wheeze, breathlessness, chest infections; superior vena cava syndrome is an emergency. |
| Neck | Visible lump; Horner syndrome (droopy eyelid, small pupil, no sweating on one side); swallowing or breathing problems. |
| Pelvis | Mass, bladder or bowel problems, leg weakness. |
| Spine (dumbbell tumours) | Back pain, leg weakness, bladder or bowel problems from cord compression; urgent. |
| Site of spread | Symptoms |
|---|---|
| Bone marrow (most common) | Pallor, tiredness, bruising, infections, bone pain, limping. |
| Bone | Pain, fractures; bruising around the eyes (“raccoon eyes”) and bulging eyes from orbital spread. |
| Liver | Swollen abdomen; rarely jaundice; can cause breathing problems in infants. |
| Lymph nodes | Firm, painless nodes. |
| Skin (infants, stage MS) | Firm, blue-purple nodules (“blueberry muffin” spots). |
| Paraneoplastic syndrome | Features | Notes |
|---|---|---|
| Opsoclonus-myoclonus syndrome | “Dancing eyes, dancing feet”: rapid eye movements, jerks, unsteadiness, irritability, sleep problems. | In about 2–3%; autoimmune; treated with steroids, ACTH, IVIG or rituximab; recovery may be incomplete. |
| VIP-related diarrhoea | Severe watery diarrhoea, dehydration, low potassium. | More common with differentiated tumours; settles after tumour removal. |
| High blood pressure | Headache, irritability; rarely seizures. | Catecholamine or renin release. |
| Other | SIADH (low sodium), Cushing-like features. | Rare. |
How quickly symptoms appear: Symptoms can build up over weeks or months (common with abdominal masses) or appear very quickly, for example with bleeding into the tumour, sudden marrow failure or OMS. Infants may only show irritability, poor feeding, slow weight gain or pallor.
Because early signs are so unspecific, a child whose “ordinary” illness does not settle as expected should be checked again by a doctor.
Diagnosis
Diagnosis involves a combination of clinical suspicion, imaging, laboratory tests, and definitive histopathological confirmation, often accompanied by molecular and genetic profiling crucial for risk stratification.
| Test | Purpose / findings |
|---|---|
| History and examination | Location signs, Horner syndrome, opsoclonus, skin nodules, blood pressure. |
| Urine HVA and VMA | Raised in about 90%; used for diagnosis and follow-up. |
| Blood tests | Blood count (marrow involvement), liver and kidney function, electrolytes, LDH, ferritin. |
| Ultrasound | Often first for an abdominal mass. |
| CT / MRI | Tumour extent and image-defined risk factors; MRI best for spinal involvement. |
| MIBG scan | Highly specific scan for primary and metastases; used for staging and response. |
| FDG or F-DOPA PET/CT | For MIBG-negative tumours. |
| Biopsy | Core needle or open biopsy for histology, stains and genetics; bone marrow from both hips. |
| Tumour genetics | MYCN amplification, 1p/11q loss, 17q gain, ploidy, ALK mutations; key for risk group. |
Staging and Risk Stratification
Staging describes how far the disease has spread. Risk stratification then combines stage with age and tumour biology to predict outcome and decide how intensive treatment needs to be.
Two staging systems are in use. The older INSS depends on how much tumour the surgeon removed, while the newer INRGSS is based on scans before any treatment and is now preferred.
| INRG stage | Definition |
|---|---|
| L1 | Localised, no image-defined risk factors, confined to one body compartment. |
| L2 | Localised with one or more image-defined risk factors (e.g. vessel encasement, spinal canal invasion). |
| M | Distant metastases (except MS). |
| MS | Under 18 months, with spread limited to skin, liver and/or bone marrow (under 10%); often regresses on its own. |
The older surgical INSS system (stages 1, 2A, 2B, 3, 4 and 4S, with 4S for infants under 12 months) is still referred to. INRG staging is decided from imaging before surgery, making results comparable between centres.
| Risk group | Typical features | Usual treatment |
|---|---|---|
| Very low | L1 without MYCN amplification; some MS with favourable biology. | Observation or surgery alone. |
| Low | L1/L2 or MS with favourable biology in young children. | Surgery or observation; chemotherapy only for symptoms. |
| Intermediate | Many L2 tumours, or stage M under 18 months, without MYCN amplification. | Moderate chemotherapy and surgery. |
| High | Stage M over 18 months; almost all MYCN-amplified tumours. | Intensive multimodal therapy. |
| Biological marker | Meaning |
|---|---|
| MYCN amplification | About 20% of tumours; strong predictor of poor outcome. |
| 11q loss | Unfavourable; older children, later relapse. |
| 1p loss, 17q gain | Unfavourable segmental changes. |
| DNA ploidy | Hyperdiploid is favourable in children under 18 months; diploid is unfavourable. |
| Histology (INPC) | Undifferentiated, high MKI is unfavourable. |
Matching treatment intensity to risk means children with favourable tumours are spared unnecessary chemotherapy, while those with aggressive disease receive the full multimodal programme.
Treatment
Treatment is highly individualized based on the assigned risk group, as outlined above. It is almost always multimodal, involving combinations of surgery, chemotherapy, radiation therapy, immunotherapy, and differentiation agents, plus supportive care.
| Risk group | Main treatment | Outcome |
|---|---|---|
| Very low / low | Surgery or observation; short chemotherapy (carboplatin, etoposide, cyclophosphamide, doxorubicin) only for symptoms or threatening complications. | Over 90% survival. |
| Intermediate | 2–8 cycles of moderate chemotherapy, then surgery; radiotherapy (about 21–24 Gy) only for selected residual disease. | Survival over 90%. |
| High | Induction chemotherapy, surgery, high-dose chemotherapy with stem cell rescue, radiotherapy, then anti-GD2 immunotherapy with isotretinoin. | Long-term survival about 50–60%. |
| Relapsed / refractory | Re-induction chemotherapy (often with dinutuximab), 131I-MIBG, ALK inhibitors, trials (CAR-T and others). | Outlook poorer. |
| High-risk phase | What it involves |
|---|---|
| Induction (about 5–6 months) | 5–6 cycles of intensive chemotherapy (COG regimens or European rapid COJEC); stem cells collected; primary tumour removed near the end. |
| Consolidation | High-dose chemotherapy (tandem thiotepa/cyclophosphamide then carboplatin/etoposide/melphalan in North America; busulfan/melphalan in Europe) with own stem cell rescue. |
| Radiotherapy | About 21.6 Gy to the tumour bed, with a boost to residual tumour. |
| Post-consolidation | Dinutuximab (or dinutuximab beta in Europe) with GM-CSF plus 6 cycles of isotretinoin; IL-2 largely dropped. |
| Maintenance | Eflornithine (DFMO) for 2 years in the US to lower relapse risk (FDA-approved 2023). |
| Total duration | About 12–18 months. |
Supportive Care: Integral throughout treatment. Includes aggressive management of nausea/vomiting, pain, mucositis, blood product transfusions (for anemia/thrombocytopenia), infection prophylaxis/antibiotics, nutritional support, management of specific syndrome symptoms (e.g., ACTH/steroids for OMS, electrolyte correction for VIP diarrhea), psychosocial support for family, and fertility preservation counseling where applicable (often considered in adolescents).
Prognosis and Long-Term Follow-Up
Prognosis is heterogeneous and primarily dictated by the risk group at diagnosis, as outlined in the treatment section. Key favorable factors include younger age (<18 months), lower stage (L1/MS), favorable histology, diploid/pseudodiploid DNA index (in infants), absence of MYCN amplification, and absence of 11q aberration. Unfavorable factors confer higher relapse risk.
| Group | Approximate 5-year survival |
|---|---|
| Very low / low risk | Over 95% |
| Intermediate risk | Over 90% |
| High risk | About 50–60% |
| Stage MS with favourable biology | About 90% |
| Stage MS with unfavourable biology | Similar to high risk |
| Relapse | Poorer; isolated local relapse does better than marrow relapse |
| Late effect | Cause | Monitoring |
|---|---|---|
| Heart damage | Doxorubicin. | Echocardiograms. |
| Hearing loss | Cisplatin, carboplatin. | Hearing tests. |
| Growth, hormone and fertility problems | Alkylating agents, radiotherapy. | Growth charts, hormone tests. |
| Learning difficulties | Intensive early treatment, hearing loss. | Neuropsychological testing. |
| Second cancers | Etoposide, alkylators, radiation. | Lifelong vigilance. |
| Kidney problems | Cisplatin, kidney removal. | Blood pressure, urine and blood tests. |
| Bone and spine problems | Radiotherapy, surgery. | Scoliosis checks. |
| Emotional problems | Cancer experience. | Psychological support. |
| OMS after-effects | Opsoclonus-myoclonus syndrome. | Neurology and learning support. |
| Follow-up | Details |
|---|---|
| Schedule | Every 1–3 months during treatment and the first year off therapy; every 3–6 months in years 2–5; then yearly. |
| Tests | Examination, urine catecholamines, imaging by risk, heart scans, hearing and hormone tests, neuropsychology. |
| Goal | Detect relapse early (rare after 2–3 years for most groups) and manage late effects. |
Resources
- Cohn, S.L. et al. (2009) ‘The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report’, Journal of Clinical Oncology, 27(2), pp. 289-297.
- Monclair, T. et al. (2009) ‘The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report’, Journal of Clinical Oncology, 27(2), pp. 298-303.
- Matthay, K.K. et al. (2016) ‘Neuroblastoma’, Nature Reviews Disease Primers, 2, 16078.
- Yu, A.L. et al. (2010) ‘Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma’, New England Journal of Medicine, 363(14), pp. 1324-1334.
- Park, J.R. et al. (2019) ‘Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial’, JAMA, 322(8), pp. 746-755.
- National Cancer Institute (2026) Neuroblastoma Treatment (PDQ®) – Health Professional Version. Available at: https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq (Accessed: October 2026).
- American Cancer Society (2026) Neuroblastoma. Available at: https://www.cancer.org/cancer/types/neuroblastoma.html (Accessed: October 2026).
- Cancer.Net (2026) Neuroblastoma – Childhood. Available at: https://www.cancer.net/cancer-types/neuroblastoma-childhood (Accessed: October 2026).
- Children’s Oncology Group (2026) Neuroblastoma. Available at: https://www.childrensoncologygroup.org/neuroblastoma (Accessed: October 2026).
Conclusion
Neuroblastoma starts in developing nerve cells, which explains why its behaviour ranges from tumours that disappear on their own to some of the most aggressive cancers of childhood.
Better understanding of its genetic drivers has changed how the disease is assessed. The integration of imaging-defined staging (INRGSS) with powerful biological markers – most notably MYCN amplification status, but also 11q status, ploidy, and histologic differentiation – allows for precise risk stratification. This precision enables tailoring of therapy: minimizing treatment for the many children with favorable disease to reduce long-term toxicity, while deploying increasingly sophisticated, multimodal regimens (including surgery, intensive chemotherapy, stem cell transplant, radiation, differentiation therapy, and groundbreaking immunotherapy like dinutuximab) for those at highest risk.
High-risk neuroblastoma is still hard to cure, but survival has improved substantially over the last two decades. Survivors need lifelong follow-up to catch relapse early and to manage the long-term effects of treatment.